Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial.

Usmani SZ, Schjesvold F, Oriol A, Karlin L, Cavo M, Rifkin RM, Yimer HA, LeBlanc R, Takezako N, McCroskey RD, Lim ABM, Suzuki K, Kosugi H, Grigoriadis G, Avivi I, Facon T, Jagannath S, Lonial S, Ghori RU, Farooqui MZH, Marinello P, San-Miguel J; KEYNOTE-185 Investigators.

Lancet Haematol. 2019 Sep;6(9):e448-e458. doi: 10.1016/S2352-3026(19)30109-7. Epub 2019 Jul 18.

PMID:
31327689
2.

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.

Mateos MV, Blacklock H, Schjesvold F, Oriol A, Simpson D, George A, Goldschmidt H, Larocca A, Chanan-Khan A, Sherbenou D, Avivi I, Benyamini N, Iida S, Matsumoto M, Suzuki K, Ribrag V, Usmani SZ, Jagannath S, Ocio EM, Rodriguez-Otero P, San Miguel J, Kher U, Farooqui M, Liao J, Marinello P, Lonial S; KEYNOTE-183 Investigators.

Lancet Haematol. 2019 Sep;6(9):e459-e469. doi: 10.1016/S2352-3026(19)30110-3. Epub 2019 Jul 18.

PMID:
31327687
3.

Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma.

Usmani SZ, Nahi H, Mateos MV, van de Donk NWCJ, Chari A, Kaufman JL, Moreau P, Oriol A, Plesner T, Benboubker L, Hellemans P, Masterson T, Clemens PL, Luo M, Liu K, San-Miguel J.

Blood. 2019 Aug 22;134(8):668-677. doi: 10.1182/blood.2019000667. Epub 2019 Jul 3.

PMID:
31270103
4.

Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies.

Mateos MV, Spencer A, Nooka AK, Pour L, Weisel K, Cavo M, Laubach JP, Cook G, Iida S, Benboubker L, Usmani SZ, Yoon SS, Bahlis NJ, Chiu C, Ukropec J, Schecter JM, Qin X, O' Rourke L, Dimopoulos MA.

Haematologica. 2019 Jun 20. pii: haematol.2019.217448. doi: 10.3324/haematol.2019.217448. [Epub ahead of print]

5.

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.

Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner CP, Weisel K, Mace JR, Raje N, Attal M, Tiab M, Macro M, Frenzel L, Leleu X, Ahmadi T, Chiu C, Wang J, Van Rampelbergh R, Uhlar CM, Kobos R, Qi M, Usmani SZ; MAIA Trial Investigators.

N Engl J Med. 2019 May 30;380(22):2104-2115. doi: 10.1056/NEJMoa1817249.

PMID:
31141632
6.

Induction Therapy for Newly Diagnosed Multiple Myeloma.

Paul B, Lipe B, Ocio EM, Usmani SZ.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:e176-e186. doi: 10.1200/EDBK_238527. Epub 2019 May 17.

PMID:
31099624
7.

A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.

Mikhael J, Richardson P, Usmani SZ, Raje N, Bensinger W, Karanes C, Campana F, Kanagavel D, Dubin F, Liu Q, Semiond D, Anderson K.

Blood. 2019 Jul 11;134(2):123-133. doi: 10.1182/blood-2019-02-895193. Epub 2019 Mar 12.

8.

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.

Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, Gupta R, Varnado W, Fiala MA, Chhabra S, Malek E, Mansour J, Paul B, Barnstead A, Kodali S, Neppalli A, Liedtke M, Narayana S, Godby KN, Kang Y, Kansagra A, Umyarova E, Scott EC, Hari P, Vij R, Usmani SZ, Callander NS, Kumar SK, Costa LJ.

Leukemia. 2019 Sep;33(9):2266-2275. doi: 10.1038/s41375-019-0435-7. Epub 2019 Mar 11.

PMID:
30858549
9.

Enhancing the feasibility of outpatient daratumumab administration via a split-dosing strategy with initial doses.

Arnall JR, Moore DC, Hill HL, Griffin S, Mueller MK, Lavery LA, Voorhees PM, Usmani SZ.

Leuk Lymphoma. 2019 Mar 8:1-4. doi: 10.1080/10428194.2019.1576871. [Epub ahead of print] No abstract available.

PMID:
30848971
10.

INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma.

Costello C, Davies FE, Cook G, Vela-Ojeda J, Omel J, Rifkin RM, Berdeja J, Puig N, Usmani SZ, Weisel K, Zonder JA, Terpos E, Spencer A, Leleu X, Boccadoro M, Thompson MA, Romanus D, Stull DM, Hungria V.

Future Oncol. 2019 May;15(13):1411-1428. doi: 10.2217/fon-2019-0013. Epub 2019 Feb 28.

11.

Mortality by a proxy performance status as defined by a claims-based measure for disability status in older patients with newly diagnosed multiple myeloma in the United States.

Li S, Natwick T, Liu J, Morrison VA, Vidito S, Werther W, Yusuf AA, Usmani SZ.

J Geriatr Oncol. 2019 May;10(3):490-496. doi: 10.1016/j.jgo.2019.01.007. Epub 2019 Jan 30.

PMID:
30709612
12.

Higher Incidence of Hemorrhagic Cystitis Following Haploidentical Related Donor Transplantation Compared with Matched Related Donor Transplantation.

Copelan OR, Sanikommu SR, Trivedi JS, Butler C, Ai J, Ragon BK, Jacobs R, Knight TG, Usmani SZ, Grunwald MR, Ghosh N, Symanowski JT, Shahid Z, Clark PE, He J.

Biol Blood Marrow Transplant. 2019 Apr;25(4):785-790. doi: 10.1016/j.bbmt.2018.12.142. Epub 2018 Dec 20.

PMID:
30579967
13.

Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma.

Gopalakrishnan S, D'Souza A, Scott E, Fraser R, Davila O, Shah N, Gale RP, Kamble R, Diaz MA, Lazarus HM, Savani BN, Hildebrandt GC, Solh M, Freytes CO, Lee C, Kyle RA, Usmani SZ, Ganguly S, Assal A, Berdeja J, Kanate AS, Dhakal B, Meehan K, Kindwall-Keller T, Saad A, Locke F, Seo S, Nishihori T, Gergis U, Gasparetto C, Mark T, Nieto Y, Kumar S, Hari P.

Biol Blood Marrow Transplant. 2019 Apr;25(4):683-688. doi: 10.1016/j.bbmt.2018.12.141. Epub 2018 Dec 21.

PMID:
30579965
14.

High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action.

Adams HC 3rd, Stevenaert F, Krejcik J, Van der Borght K, Smets T, Bald J, Abraham Y, Ceulemans H, Chiu C, Vanhoof G, Usmani SZ, Plesner T, Lonial S, Nijhof I, Lokhorst HM, Mutis T, van de Donk NWCJ, Sasser AK, Casneuf T.

Cytometry A. 2019 Mar;95(3):279-289. doi: 10.1002/cyto.a.23693. Epub 2018 Dec 11.

15.

Daratumumab, pomalidomide and dexamethasone combination therapy in daratumumab and/or pomalidomide refractory multiple myeloma.

Hussain MJ, Robinson MM, Hamadeh I, Arnall J, Bhutani M, Atrash S, Friend R, Pineda-Roman M, Symanowski JT, Usmani SZ, Voorhees PM.

Br J Haematol. 2019 Jul;186(1):140-144. doi: 10.1111/bjh.15716. Epub 2018 Dec 11. No abstract available.

PMID:
30536372
16.

Treatment approach for young, fit, newly diagnosed multiple myeloma patients.

Usmani SZ, Seifter E.

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):97-102. doi: 10.1182/asheducation-2018.1.97. Review. No abstract available.

PMID:
30504297
17.

Peripheral Immunotype Correlates with Minimal Residual Disease Status and Is Modulated by Immunomodulatory Drugs in Multiple Myeloma.

Bhutani M, Foureau D, Zhang Q, Robinson M, Wynn AS, Steuerwald NM, Druhan LJ, Guo F, Rigby K, Turner M, Slaughter D, Friend R, Atrash S, Symanowski JT, Avalos BR, Copelan EA, Voorhees PM, Usmani SZ.

Biol Blood Marrow Transplant. 2019 Mar;25(3):459-465. doi: 10.1016/j.bbmt.2018.11.015. Epub 2018 Nov 24.

PMID:
30481597
18.

Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement.

Arnall JR, Usmani SZ, Adamu H, Mishkin J, Bhutani M.

J Oncol Pharm Pract. 2019 Jun;25(4):1021-1025. doi: 10.1177/1078155218815305. Epub 2018 Nov 26.

PMID:
30477388
19.

Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project.

Usmani SZ, Hoering A, Cavo M, Miguel JS, Goldschimdt H, Hajek R, Turesson I, Lahuerta JJ, Attal M, Barlogie B, Lee JH, Kumar S, Lenhoff S, Morgan G, Rajkumar SV, Durie BGM, Moreau P.

Blood Cancer J. 2018 Nov 23;8(12):123. doi: 10.1038/s41408-018-0155-7.

20.

Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma.

Atrash S, Robinson M, Slaughter D, Aneralla A, Brown T, Robinson J, Ndiaye A, Sprouse C, Zhang Q, Symanowski JT, Friend R, Voorhees PM, Usmani SZ, Bhutani M.

Blood Cancer J. 2018 Nov 8;8(11):107. doi: 10.1038/s41408-018-0144-x. No abstract available.

21.

Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma.

Chari A, Lonial S, Mark TM, Krishnan AY, Stockerl-Goldstein KE, Usmani SZ, Londhe A, Etheredge D, Fleming S, Liu B, Ukropec J, Lin TS, Jagannath S, Nooka AK.

Cancer. 2018 Nov 15;124(22):4342-4349. doi: 10.1002/cncr.31706. Epub 2018 Nov 5.

22.

CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance.

van de Donk NWCJ, Usmani SZ.

Front Immunol. 2018 Sep 20;9:2134. doi: 10.3389/fimmu.2018.02134. eCollection 2018. Review.

23.

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX.

Dimopoulos MA, San-Miguel J, Belch A, White D, Benboubker L, Cook G, Leiba M, Morton J, Ho PJ, Kim K, Takezako N, Moreau P, Kaufman JL, Sutherland HJ, Lalancette M, Magen H, Iida S, Kim JS, Prince HM, Cochrane T, Oriol A, Bahlis NJ, Chari A, O'Rourke L, Wu K, Schecter JM, Casneuf T, Chiu C, Soong D, Sasser AK, Khokhar NZ, Avet-Loiseau H, Usmani SZ.

Haematologica. 2018 Dec;103(12):2088-2096. doi: 10.3324/haematol.2018.194282. Epub 2018 Sep 20.

24.

Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups.

Scott EC, Hari P, Kumar S, Fraser R, Davila O, Shah N, Gale RP, Diaz MA, Agrawal V, Cornell RF, Ganguly S, Akpek G, Freytes C, Hashmi S, Malek E, Kamble RT, Lazarus H, Solh M, Usmani SZ, Kanate AS, Saad A, Chhabra S, Gergis U, Cerny J, Kyle RA, Lee C, Kindwall-Keller T, Assal A, Hildebrandt GC, Holmberg L, Maziarz RT, Nishihori T, Seo S, Kumar S, Mark T, D'Souza A.

Biol Blood Marrow Transplant. 2018 Dec;24(12):2443-2449. doi: 10.1016/j.bbmt.2018.08.013. Epub 2018 Aug 22.

PMID:
30142419
25.

Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma.

Chari A, Larson S, Holkova B, Cornell RF, Gasparetto C, Karanes C, Matous JV, Niesvizky R, Valent J, Lunning M, Usmani SZ, Anderson LD Jr, Chang L, Lee Y, Pak Y, Salman Z, Graef T, Bilotti E, Chhabra S.

Leuk Lymphoma. 2018 Nov;59(11):2588-2594. doi: 10.1080/10428194.2018.1443337. Epub 2018 Apr 4.

PMID:
29616843
26.

Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma.

Usmani SZ, Khan I, Chiu C, Foureau D, Druhan LJ, Rigby K, Casneuf T, Sasser AK.

Exp Hematol Oncol. 2018 Feb 7;7:3. doi: 10.1186/s40164-018-0096-7. eCollection 2018.

27.

Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma.

van de Donk NWCJ, Casneuf T, Di Cara A, Parren PW, Zweegman S, van Kessel B, Lokhorst HM, Usmani SZ, Lonial S, Richardson PG, Chiu C, Mutis T, Nijhof IS, Sasser AK.

Br J Haematol. 2019 Feb;184(3):475-479. doi: 10.1111/bjh.15122. Epub 2018 Feb 7. No abstract available.

PMID:
29411874
28.

Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis.

Dhakal B, Szabo A, Chhabra S, Hamadani M, D'Souza A, Usmani SZ, Sieracki R, Gyawali B, Jackson JL, Asimakopoulos F, Hari PN.

JAMA Oncol. 2018 Mar 1;4(3):343-350. doi: 10.1001/jamaoncol.2017.4600.

29.

BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee.

Holstein SA, Avet-Loiseau H, Hahn T, Ho CM, Lohr JG, Munshi NC, Paiva B, Pasquini MC, Tario JD Jr, Usmani SZ, Wallace PK, Weisel K, McCarthy PL.

Biol Blood Marrow Transplant. 2018 Apr;24(4):641-648. doi: 10.1016/j.bbmt.2017.12.774. Epub 2017 Dec 11. Review.

30.

Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival.

Htut M, D'Souza A, Krishnan A, Bruno B, Zhang MJ, Fei M, Diaz MA, Copelan E, Ganguly S, Hamadani M, Kharfan-Dabaja M, Lazarus H, Lee C, Meehan K, Nishihori T, Saad A, Seo S, Ramanathan M, Usmani SZ, Gasparetto C, Mark TM, Nieto Y, Hari P.

Biol Blood Marrow Transplant. 2018 Mar;24(3):478-485. doi: 10.1016/j.bbmt.2017.10.024. Epub 2017 Oct 24.

31.

Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials.

Bhutani M, Zhang Q, Friend R, Voorhees PM, Druhan LJ, Barlogie B, Sonneveld P, Morgan GJ, Symanowski JT, Avalos BR, Copelan EA, Usmani SZ.

Lancet Haematol. 2017 Sep;4(9):e443-e451. doi: 10.1016/S2352-3026(17)30143-6.

PMID:
28863804
32.

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study.

Kumar SK, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H, Hillengass J, Leleu X, Beksac M, Alsina M, Oriol A, Cavo M, Ocio EM, Mateos MV, O'Donnell EK, Vij R, Lokhorst HM, van de Donk NWCJ, Min C, Mark T, Turesson I, Hansson M, Ludwig H, Jagannath S, Delforge M, Kyriakou C, Hari P, Mellqvist U, Usmani SZ, Dytfeld D, Badros AZ, Moreau P, Kim K, Otero PR, Lee JH, Shustik C, Waller D, Chng WJ, Ozaki S, Lee JJ, de la Rubia J, Eom HS, Rosinol L, Lahuerta JJ, Sureda A, Kim JS, Durie BGM.

Leukemia. 2017 Nov;31(11):2443-2448. doi: 10.1038/leu.2017.138. Epub 2017 May 12.

PMID:
28620163
33.

Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment comparison.

Usmani SZ, Diels J, Ito T, Mehra M, Khan I, Lam A.

Am J Hematol. 2017 Aug;92(8):E146-E152. doi: 10.1002/ajh.24781. Epub 2017 Jun 5.

34.

Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report.

Schriber JR, Hari PN, Ahn KW, Fei M, Costa LJ, Kharfan-Dabaja MA, Angel-Diaz M, Gale RP, Ganguly S, Girnius SK, Hashmi S, Pawarode A, Vesole DH, Wiernik PH, Wirk BM, Marks DI, Nishihori T, Olsson RF, Usmani SZ, Mark TM, Nieto YL, D'Souza A.

Cancer. 2017 Aug 15;123(16):3141-3149. doi: 10.1002/cncr.30747. Epub 2017 May 4.

35.

Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group.

Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, Hillengass J, Engelhardt M, Usmani SZ, Vesole DH, San-Miguel J, Kumar SK, Richardson PG, Mikhael JR, da Costa FL, Dimopoulos MA, Zingaretti C, Abildgaard N, Goldschmidt H, Orlowski RZ, Chng WJ, Einsele H, Lonial S, Barlogie B, Anderson KC, Rajkumar SV, Durie BGM, Zamagni E.

Lancet Oncol. 2017 Apr;18(4):e206-e217. doi: 10.1016/S1470-2045(17)30189-4. Review.

PMID:
28368259
36.

Clinical potential of SLAMF7 antibodies - focus on elotuzumab in multiple myeloma.

Friend R, Bhutani M, Voorhees PM, Usmani SZ.

Drug Des Devel Ther. 2017 Mar 20;11:893-900. doi: 10.2147/DDDT.S98053. eCollection 2017. Review.

37.

Practical Considerations in Managing Relapsed Multiple Myeloma.

Agarwal A, Chow E, Bhutani M, Voorhees PM, Friend R, Usmani SZ.

Clin Lymphoma Myeloma Leuk. 2017 Feb;17(2):69-77. doi: 10.1016/j.clml.2016.11.010. Epub 2016 Nov 23. Review.

PMID:
27986429
38.

The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia.

Jacobs RW, Awan FT, Leslie LA, Usmani SZ, Ghosh N.

Expert Rev Hematol. 2016 Dec;9(12):1177-1187. Epub 2016 Nov 14. Review.

PMID:
27791448
39.

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Lisby S, Khokhar NZ, O'Rourke L, Chiu C, Qin X, Guckert M, Ahmadi T, Moreau P; POLLUX Investigators.

N Engl J Med. 2016 Oct 6;375(14):1319-1331.

40.

Maintenance lenalidomide after transplantation: How much is enough?

Usmani SZ.

Cancer. 2016 Dec 15;122(24):3762-3764. doi: 10.1002/cncr.30363. Epub 2016 Sep 28. No abstract available.

41.
42.

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.

Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Bladé J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS, Avet-Loiseau H.

Lancet Oncol. 2016 Aug;17(8):e328-e346. doi: 10.1016/S1470-2045(16)30206-6. Review.

PMID:
27511158
43.

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.

Usmani SZ, Weiss BM, Plesner T, Bahlis NJ, Belch A, Lonial S, Lokhorst HM, Voorhees PM, Richardson PG, Chari A, Sasser AK, Axel A, Feng H, Uhlar CM, Wang J, Khan I, Ahmadi T, Nahi H.

Blood. 2016 Jul 7;128(1):37-44. doi: 10.1182/blood-2016-03-705210. Epub 2016 May 23.

44.

Cutaneous manifestations of multiple myeloma and other plasma cell proliferative disorders.

Bhutani M, Shahid Z, Schnebelen A, Alapat D, Usmani SZ.

Semin Oncol. 2016 Jun;43(3):395-400. doi: 10.1053/j.seminoncol.2016.02.017. Epub 2016 Feb 23. Review.

PMID:
27178694
45.

Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling.

Zhang XD, Baladandayuthapani V, Lin H, Mulligan G, Li B, Esseltine DW, Qi L, Xu J, Hunziker W, Barlogie B, Usmani SZ, Zhang Q, Crowley J, Hoering A, Shah JJ, Weber DM, Manasanch EE, Thomas SK, Li BZ, Wang HH, Zhang J, Kuiatse I, Tang JL, Wang H, He J, Yang J, Milan E, Cenci S, Ma WC, Wang ZQ, Davis RE, Yang L, Orlowski RZ.

Cancer Cell. 2016 May 9;29(5):639-652. doi: 10.1016/j.ccell.2016.03.026. Epub 2016 Apr 28.

46.

Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice.

Jurczyszyn A, Grzasko N, Gozzetti A, Czepiel J, Cerase A, Hungria V, Crusoe E, Silva Dias AL, Vij R, Fiala MA, Caers J, Rasche L, Nooka AK, Lonial S, Vesole DH, Philip S, Gangatharan S, Druzd-Sitek A, Walewski J, Corso A, Cocito F, Vekemans MC, Atilla E, Beksac M, Leleu X, Davila J, Badros A, Aneja E, Abildgaard N, Kastritis E, Fantl D, Schutz N, Pika T, Butrym A, Olszewska-Szopa M, Usnarska-Zubkiewicz L, Usmani SZ, Nahi H, Chim CS, Shustik C, Madry K, Lentzsch S, Swiderska A, Helbig G, Guzicka-Kazimierczak R, Lendvai N, Waage A, Andersen KT, Murakami H, Zweegman S, Castillo JJ.

Am J Hematol. 2016 Jun;91(6):575-80. doi: 10.1002/ajh.24351. Epub 2016 Apr 24.

47.

Successful Treatment of Hepatitis C Infection While Receiving Concurrent Chemotherapy for AL Amyloidosis.

Chow E, Shahid Z, Smith ET Jr, Kamionek M, Usmani SZ.

Clin Lymphoma Myeloma Leuk. 2016 Apr;16(4):237-9. doi: 10.1016/j.clml.2016.01.003. Epub 2016 Jan 18. No abstract available.

PMID:
26869507
48.

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.

Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, Belch A, Krishnan A, Vescio RA, Mateos MV, Mazumder A, Orlowski RZ, Sutherland HJ, Bladé J, Scott EC, Oriol A, Berdeja J, Gharibo M, Stevens DA, LeBlanc R, Sebag M, Callander N, Jakubowiak A, White D, de la Rubia J, Richardson PG, Lisby S, Feng H, Uhlar CM, Khan I, Ahmadi T, Voorhees PM.

Lancet. 2016 Apr 9;387(10027):1551-1560. doi: 10.1016/S0140-6736(15)01120-4. Epub 2016 Jan 7.

PMID:
26778538
49.

Bone marrow abnormalities and early bone lesions in multiple myeloma and its precursor disease: a prospective study using functional and morphologic imaging.

Bhutani M, Turkbey B, Tan E, Korde N, Kwok M, Manasanch EE, Tageja N, Mailankody S, Roschewski M, Mulquin M, Carpenter A, Lamping E, Minter AR, Weiss BM, Mena E, Lindenberg L, Calvo KR, Maric I, Usmani SZ, Choyke PL, Kurdziel K, Landgren O.

Leuk Lymphoma. 2016 May;57(5):1114-21. doi: 10.3109/10428194.2015.1090572. Epub 2016 Apr 7.

50.

Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma.

Usmani SZ, Cavenagh JD, Belch AR, Hulin C, Basu S, White D, Nooka A, Ervin-Haynes A, Yiu W, Nagarwala Y, Berger A, Pelligra CG, Guo S, Binder G, Gibson CJ, Facon T.

J Med Econ. 2016;19(3):243-58. doi: 10.3111/13696998.2015.1115407. Epub 2015 Nov 17.

PMID:
26517601

Supplemental Content

Loading ...
Support Center